MARKET

EVMN

EVMN

EVOMMUNE INC
NYSE
20.65
+0.60
+2.99%
After Hours: 20.65 0 0.00% 16:10 06/17 EDT
OPEN
20.24
PREV CLOSE
20.05
HIGH
20.94
LOW
19.73
VOLUME
600.36K
TURNOVER
--
52 WEEK HIGH
33.20
52 WEEK LOW
13.89
MARKET CAP
743.78M
P/E (TTM)
-32.0802
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at EVMN last week (0608-0612)?
Weekly Report · 2d ago
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN), Immunome (IMNM) and Alcon (ALC)
TipRanks · 5d ago
Analysts Offer Insights on Healthcare Companies: Evommune, Inc. (EVMN) and Alterity Therapeutics (ATHE)
TipRanks · 06/10 18:20
Weekly Report: what happened at EVMN last week (0601-0605)?
Weekly Report · 06/08 10:38
Evommune Stockholders Reelect Directors and Ratify Auditor
TipRanks · 06/02 21:31
Weekly Report: what happened at EVMN last week (0525-0529)?
Weekly Report · 06/01 10:44
Evommune Price Target Maintained With a $50.00/Share by HC Wainwright & Co.
Dow Jones · 05/26 11:03
Evommune Buy Rating Reiterated by Kapoor on EVO756 CSU Catalyst; 12-Month Price Target Maintained at $50
TipRanks · 05/26 10:27
More
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.

Webull offers Evommune, Inc. stock information, including NYSE: EVMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVMN stock methods without spending real money on the virtual paper trading platform.